Belpointe Asset Management LLC Has $3.30 Million Stock Holdings in Pfizer Inc. $PFE

Key Points

• Belpointe Asset Management LLC reduced its holdings in Pfizer Inc. by 43.8% during the 1st quarter, leaving them with 130,103 shares valued at approximately $3.3 million.
• Pfizer's quarterly earnings exceeded expectations, reporting $0.78 earnings per share compared to the consensus estimate of $0.58, along with revenues of $14.65 billion for the quarter.
• The company also declared a quarterly dividend of $0.43, representing an annualized yield of 7.0% and a dividend payout ratio of 91.49%.

Belpointe Asset Management LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 43.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 130,103 shares of the biopharmaceutical company's stock after selling 101,295 shares during the period. Belpointe Asset Management LLC's holdings in Pfizer were worth $3,297,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. Brighton Jones LLC raised its holdings in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares during the period. Triumph Capital Management lifted its position in shares of Pfizer by 20.0% in the 4th quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company's stock worth $273,000 after acquiring an additional 1,717 shares during the period. Gotham Asset Management LLC lifted its position in shares of Pfizer by 333.4% in the 4th quarter. Gotham Asset Management LLC now owns 141,040 shares of the biopharmaceutical company's stock worth $3,742,000 after acquiring an additional 108,494 shares during the period. Finally, Janus Henderson Group PLC lifted its position in shares of Pfizer by 80.7% in the 4th quarter. Janus Henderson Group PLC now owns 958,315 shares of the biopharmaceutical company's stock worth $25,434,000 after acquiring an additional 427,886 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 1.1%

NYSE:PFE traded up $0.27 during trading hours on Thursday, hitting $24.84. 36,770,116 shares of the stock were exchanged, compared to its average volume of 34,782,688. The company's 50 day moving average is $24.82 and its two-hundred day moving average is $24.32. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $141.23 billion, a P/E ratio of 13.21, a price-to-earnings-growth ratio of 0.87 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the business earned $0.60 EPS. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer's dividend payout ratio is currently 91.49%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on PFE shares. Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Bank of America upped their price objective on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Berenberg Bank reduced their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Citigroup raised their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, HSBC dropped their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.